Elizabeth L. Hardaker
Oncology R&D
Cambridge, ENG, United Kingdom
Cambridge, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Elucidating the relationship between affinity and potency in the performance of therapeutic IgE.
Journal: Scientific reports
Published: January 06, 2026
Hybrid IgE-IgG1 antibodies (IgEG): a new antibody class that combines IgE and IgG functionality.
Journal: mAbs
Published: May 16, 2025
Fc-mediated immune stimulating, pro-inflammatory and antitumor effects of anti-HER2 IgE against HER2-expressing and trastuzumab-resistant tumors.
Journal: Journal for immunotherapy of cancer
Published: January 15, 2025
An IgE antibody targeting HER2 identified by clonal selection restricts breast cancer growth via immune-stimulating activities.
Journal: Journal of experimental & clinical cancer research : CR
Published: November 08, 2024
Efficacy and pharmacodynamic effect of anti-CD73 and anti-PD-L1 monoclonal antibodies in combination with cytotoxic therapy: observations from mouse tumor models.
Journal: Cancer biology & therapy
Published: January 11, 2024
Optimization of an Imidazo[1,2-a]pyridine Series to Afford Highly Selective Type I1/2 Dual Mer/Axl Kinase Inhibitors with In Vivo Efficacy.
Journal: Journal of medicinal chemistry
Published: September 03, 2021
Generating Selective Leads for Mer Kinase Inhibitors-Example of a Comprehensive Lead-Generation Strategy.
Journal: Journal of medicinal chemistry
Published: March 08, 2021
Development of autotaxin inhibitors: A series of tetrazole cinnamides.
Journal: Bioorganic & medicinal chemistry letters
Published: September 15, 2020
Development of an ObLiGaRe Doxycycline Inducible Cas9 system for pre-clinical cancer drug discovery.
Development of an ObLiGaRe Doxycycline Inducible Cas9 system for pre-clinical cancer drug discovery.
Journal: Nature communications
Published: March 23, 2020
Last Updated: 09/26/2026